V Square Quantitative Management LLC Reduces Position in Edwards Lifesciences Corporation $EW

V Square Quantitative Management LLC lessened its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 2.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,320 shares of the medical research company’s stock after selling 311 shares during the period. V Square Quantitative Management LLC’s holdings in Edwards Lifesciences were worth $1,198,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of EW. Brighton Jones LLC purchased a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $266,000. Versant Capital Management Inc boosted its position in shares of Edwards Lifesciences by 9.3% during the first quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company’s stock valued at $123,000 after buying an additional 145 shares during the period. AdvisorNet Financial Inc boosted its position in shares of Edwards Lifesciences by 11.5% during the first quarter. AdvisorNet Financial Inc now owns 1,663 shares of the medical research company’s stock valued at $121,000 after buying an additional 172 shares during the period. GAMMA Investing LLC boosted its position in shares of Edwards Lifesciences by 7,061.2% during the first quarter. GAMMA Investing LLC now owns 340,946 shares of the medical research company’s stock valued at $24,712,000 after buying an additional 336,185 shares during the period. Finally, Rothschild Investment LLC boosted its holdings in shares of Edwards Lifesciences by 1.3% in the first quarter. Rothschild Investment LLC now owns 13,149 shares of the medical research company’s stock valued at $953,000 after purchasing an additional 168 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 4,114 shares of the company’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.34% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $76.34 on Monday. The company has a market capitalization of $44.82 billion, a price-to-earnings ratio of 10.98, a price-to-earnings-growth ratio of 3.67 and a beta of 1.07. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The firm has a 50 day moving average of $78.50 and a 200 day moving average of $75.78.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. Edwards Lifesciences’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on EW. BTIG Research upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price target for the company in a report on Tuesday, July 29th. William Blair upgraded Edwards Lifesciences to a “strong-buy” rating in a report on Friday, July 25th. Wall Street Zen lowered Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a report on Monday. Canaccord Genuity Group boosted their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the company a “hold” rating in a report on Friday, July 25th. Finally, JPMorgan Chase & Co. boosted their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $86.61.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.